No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Everest Medicines Limited operates as a biopharmaceutical firm, concentrating its efforts on bringing innovative treatments to market. The company handles the entire process, from identifying and acquiring promising drug candidates to developing them through clinical trials and ultimately commercializing them. Its core objective is to address significant gaps in existing medical treatments within the broader Asia Pacific region, with a particular focus on Greater China. The company boasts a strong portfolio, including eleven experimental drug candidates currently undergoing clinical evaluation. These investigational therapies are designed to combat a range of serious conditions, including various forms of cancer (oncology), immune system disorders (immunology), heart and kidney ailments (cardio-renal), and infectious diseases. Everest Medicines Limited was founded in 2017 and is based in Shanghai, China.
www.everestmedicines.comNo one on the platform currently holds 1952.HK.
No tracked institution reports a position in 1952.HK as of their last filing.
No one on the platform has traded 1952.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 141.5% | |||||
| Profit Margin % | -17.4% | -374153.3% | ||||
| Free Cash Flow Margin % | -10.1% | -634431.1% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3.2B | +83.6% | $1.01 | $0.80–$1.33 | — | 1 |
| 2027 | $4.2B | +29.1% | $1.05 | $0.83–$1.38 | — | 2 |
| 2028 | $6.0B | +43.3% | $2.63 | $2.47–$2.78 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-17 | $-1.07 | $-0.02 | +97.8% |
| 2026-03-24 | $0.11 | $-0.13 | -220.0% |
| 2025-08-27 | $-1.11 | $-0.84 | +23.8% |
| 2025-03-24 | $-1.34 | $-1.35 | -0.8% |
| 2024-08-27 | $-1.09 | $-2.12 | -95.0% |
| 2024-03-26 | $-1.91 | $-1.47 | +23.0% |
| 2023-08-22 | $-2.28 | $-1.51 | +33.6% |
| $5.97 |
| +0.00% |
| $9.6B |
| — |
| 6185.HKCanSino Biologics Inc. | $25.56 | -3.40% | $8.9B | — |
| 6855.HKAscentage Pharma Group International | $30.94 | -3.49% | $11.5B | — |
Source: Financial Modeling Prep · peers by sector/industry